View Future GrowthEntropy Neurodynamics 過去の業績過去 基準チェック /06Entropy Neurodynamicsは14.7%の年平均成長率で業績を伸ばしているが、Pharmaceuticals業界はgrowingで9.4%毎年増加している。売上は成長しており、年平均103.7%の割合である。主要情報14.71%収益成長率51.68%EPS成長率Pharmaceuticals 業界の成長5.95%収益成長率103.67%株主資本利益率-59.62%ネット・マージン-299.58%前回の決算情報31 Dec 2025最近の業績更新更新なしすべての更新を表示Recent updatesお知らせ • Nov 05Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 165,588,236 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,823,528 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Transaction Features: Subsequent Direct Listingお知らせ • Sep 16Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025. Location: suite 1.01 117 camberwell road, hawthorn east vic 3123, Australiaお知らせ • Mar 31Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Nov 06Tryptamine Therapeutics Limited Announces Peter Molloy to Resign as Non-Executive Director from the Board, Effective November 8, 2024Tryptamine Therapeutics Limited announced that Non-Executive Director Mr. Peter Molloy will resign from the Board of Directors. Mr. Molloy's resignation follows the Company's strategic placement to raise $6 million to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr. Daniel Tillett as a Non-Executive Director. Mr. Molloy has been a member of the Company since September 2020 and was influential in Tryp's growth trajectory. He provided valued support in the Company's transition to the Australian Securities Exchange. Dr. Tillett's appointment and Mr. Molloy's resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for November 8, 2024.お知らせ • Nov 01Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listingお知らせ • Sep 06Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024.お知らせ • Sep 03Tryptamine Therapeutics Limited Announces Chief Financial Officer ChangesTryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer (‘CFO’), effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has resigned. Mr. George is a Director at Bio101 Financial Advisory (‘Bio101’). He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr. George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Company announced that Mr. Jim O'Neill provided wide-ranging support to advance the transition of roles to Mr. George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024.収支内訳Entropy Neurodynamics の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史OTCPK:TYPT.F 収益、費用、利益 ( )AUD Millions日付収益収益G+A経費研究開発費31 Dec 252-54030 Sep 252-54030 Jun 252-54030 Jun 241-73029 Feb 240-53-230 Nov 230-53231 Aug 230-62031 May 230-72428 Feb 230-62430 Nov 220-73431 Aug 220-85331 May 220-96228 Feb 220-118230 Nov 210-129231 Aug 210-97131 May 210-650質の高い収益: TYPT.Fは現在利益が出ていません。利益率の向上: TYPT.Fは現在利益が出ていません。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: TYPT.Fは利益を出していないが、過去 5 年間で年間14.7%の割合で損失を削減してきた。成長の加速: TYPT.Fの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。収益対業界: TYPT.Fは利益が出ていないため、過去 1 年間の収益成長をPharmaceuticals業界 ( -4.8% ) と比較することは困難です。株主資本利益率高いROE: TYPT.Fは現在利益が出ていないため、自己資本利益率 ( -59.62% ) はマイナスです。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/27 06:25終値2026/05/27 00:00収益2025/12/31年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Entropy Neurodynamics Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。1 アナリスト機関Michael HigginsLadenburg Thalmann & Company
お知らせ • Nov 05Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6.1 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 165,588,236 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 13,823,528 Price\Range: AUD 0.034 Discount Per Security: AUD 0.00204 Transaction Features: Subsequent Direct Listing
お知らせ • Sep 16Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025Tryptamine Therapeutics Limited, Annual General Meeting, Nov 13, 2025. Location: suite 1.01 117 camberwell road, hawthorn east vic 3123, Australia
お知らせ • Mar 31Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has completed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Nov 06Tryptamine Therapeutics Limited Announces Peter Molloy to Resign as Non-Executive Director from the Board, Effective November 8, 2024Tryptamine Therapeutics Limited announced that Non-Executive Director Mr. Peter Molloy will resign from the Board of Directors. Mr. Molloy's resignation follows the Company's strategic placement to raise $6 million to fast track its TRP-8803 (IV-infused psilocin) clinical trial strategy, which has also led to the pending appointment of Dr. Daniel Tillett as a Non-Executive Director. Mr. Molloy has been a member of the Company since September 2020 and was influential in Tryp's growth trajectory. He provided valued support in the Company's transition to the Australian Securities Exchange. Dr. Tillett's appointment and Mr. Molloy's resignation will occur after the conclusion of the Company Annual General Meeting, scheduled for November 8, 2024.
お知らせ • Nov 01Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million.Tryptamine Therapeutics Limited has filed a Follow-on Equity Offering in the amount of AUD 6 million. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 137,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 162,500,000 Price\Range: AUD 0.02 Discount Per Security: AUD 0.0012 Security Features: Attached Options Transaction Features: Subsequent Direct Listing
お知らせ • Sep 06Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024Tryptamine Therapeutics Limited, Annual General Meeting, Nov 08, 2024.
お知らせ • Sep 03Tryptamine Therapeutics Limited Announces Chief Financial Officer ChangesTryptamine Therapeutics Limited advised that Mr. Hamish George has been appointed Chief Financial Officer (‘CFO’), effective 1 September 2024. As part of the appointment, previous CFO Mr. Jim O'Neill has resigned. Mr. George is a Director at Bio101 Financial Advisory (‘Bio101’). He has over 10 years of finance and commercial experience working with public and private companies in Australia and abroad. Mr. George currently serves as CFO and Company Secretary for several ASX-listed, private companies and not-for-profits. He holds a Bachelor of Commerce from the University of Melbourne, a Masters Degree in Professional Accounting from RMIT, a Certificate in Governance Practice from the Governance Institute of Australia and is a qualified Chartered Accountant. The Company announced that Mr. Jim O'Neill provided wide-ranging support to advance the transition of roles to Mr. George during August 2024, enabling him to be fully engaged as CFO from 1 September 2024.